Tech Company Financing Transactions
Phathom Pharmaceuticals Funding Round
Phathom Pharmaceuticals, operating out of Menlo Park, secured $140 million from Frazier Healthcare Partners, Abingworth and BVF Partners.
Transaction Overview
Company Name
Announced On
5/16/2019
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$140,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
70 Willow Rd. 200
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Phathom Pharmaceuticals (Nasdaq: PHAT), launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Tadataka Yamada
Chief Executive Officer
David Socks
Chief Operating Officer
Azmi Nabulsi
Chief Scientific Officer
Roger Ulrich
VP - Bus. Development
Aditya Kohli
Browse more venture capital transactions:
Prev: 5/16/2019: Paradigm Diagnostics venture capital transaction
Next: 5/16/2019: BioClarity venture capital transaction
Share this article
About Our VC Transactions Data
We document every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs